Targeting farnesyltransferase: Is Ras relevant?

Drug Resistance Updates

Volumn 2, Issue 2, 1999, Pages 81-84

  Prendergast, George C ^a   Du, Wei ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN;

CANCER CHEMOTHERAPY; CELL ADHESION; DRUG ACTIVITY; DRUG TARGETING; MALIGNANT TRANSFORMATION; ONCOGENE RAS; PRENYLATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; SHORT SURVEY;

EID: 0032981812     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0070     Document Type: Article

References (38)

1. Gibbs J., Oliff A., Kohl N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell. 77:1994;175-178.
2. Casey P. J., Seabra M. C. Protein prenyltransferases. J Biol Chem. 271:1996;5289-5292.
3. Zhang FL and Casey P. J. Protein prenylation: molecular mechanisms and functional consequences. Ann Rev Biochem. 65:1996;241-269.
4. Kato K., Cox A. D., Hisaka M. M., Graham S. M., Buss J. E., Der C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA. 89:1992;6403-6407.
5. Gibbs J. B., Oliff A. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Ann Rev Pharm Tox. 37:1997;143-166.
6. Garcia A. M., Rowell C., Ackermann K., Kowalczyk J. J., Lewis M. D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J Biol Chem. 268:1993;18415-18418.
7. James G. L., Goldstein J. L., Brown M. S. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science. 260:1993;1937-1942.
8. Prendergast G. C., Davide J. P., deSolms S. J. Farnesyltransferase inhibition causes morphological reversion of ras -transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol. 14:1994;4193-4202.
9. Kohl N. E., Mosser S. D., deSolms S. J. Selective inhibition of ras -dependent transformation by a farnesyltransferase inhibitor. Science. 260:1993;1934-1937.
10. Kohl N. E., Omer C. A., Conner M. W. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1:1995;792-797.
11. Kohl N. E., Redner F., Mosser S. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA. 91:1994;9141-9145.
12. Liu M., Bryant M. S., Chen J. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 58:1998;4947-4956.
13. Mangues R., Corral T., Kohl N. E. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 58:1998;1253-1259.
14. Nagasu T., Yoshimatsu K., Rowell C., Lewis M. D., Garcia A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res. 55:1995;5310-5314.
15. Barrington R. E., Subler M. A., Rands E. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol, 18:1998;85-92.
16. Lebowitz P. F., Sakamuro D., Prendergast G. C. Farnesyltransferase inhibitors induce apoptosis in Ras-transformed cells denied substratum attachment. Cancer Res. 57:1997;708-713.
17. Lebowitz P. F., Prendergast G. C. Non-Ras targets for farnesyltransferase inhibitors: focus on Rho. Oncogene. 17:1998;1439-1447.
18. Ulsh L. S., Shih T. Y. Metabolic turnover of human c-rasH p21 protein of EJ bladder carcinoma and its normal cellular and viral homologs. Mol Cell Biol. 4:1984;1647-1652.
19. Lerner E. C., Zhang T. T., Knowles D. B., Qian Y. M., Hamilton A. D., Sebti S. M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase-I inhibitor in human tumor cell lines. Oncogene. 15:1997;1283-1288.
20. Sepp-Lorenzino L., Ma Z., Rands E. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines. Cancer Res. 55:1995;5302-5309.
21. Whyte D. B., Kirschmeier P., Hockenberry T. N. K- and N-ras geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 272:1997;14459-14464.
22. Cox A. D., Garcia A. M., Westwick J. K. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristoylated, oncogenic ras signaling and transformation. J Biol Chem. 269:1994;1-4.
23. Lebowitz P. F., Davide J. P., Prendergast G. C. Evidence that farnesyl transferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol Cell Biol. 15:1995;6613-6622.
24. Symons M. Rho family GTPases: the cytoskeleton and beyond. Trends Biochem Sci. 21:1996;178-181.
25. Gomez J., Martinez A. C., Gonzalez A., Rebollo A. Dual role of Ras and Rho proteins: at the cutting edge of life and death. Immunol. Cell Biol. 76:1998;125-134.
26. Lebowitz P. F., Casey P. J., Prendergast G. C., Thissen J. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem. 272:1997;15591-15594.
27. Prendergast G. C., Khosravi-Far R., Solski P., Kurzawa H., Lebowitz P. F., Der C. J. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene. 10:1995;2289-2296.
28. Du W., Lebowitz P. F., Prendergast G. C. Cell growth inhibition by farnesyltransferase inhibitors in mediated by gain of geranylgeranylated RhoB. Mol Cell Biol. 19:1999;1831-1840.
29. Du, W. Prendergast, G. C. Gain of geranylgeranylated RhoB mediates growth inhibition by farnesyltransferase inhibitors in human tumor cells.
30. Prendergast G. C., Davide J. P., Lebowitz P. F., Wechsler-Reya R., Kohl N. E. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res. 56:1996;2626-2632.
31. Bellacosa A., de Feo D., Godwin A. K. Molecular alterations of the akt2 oncogene in ovarian and breast carcinomas. Int J Cancer. 64:1995;280-285.
32. Suwa H., Ohshio G., Imamura T. Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer. 77:1998;147-152.
33. Wu X., Senechal K., Neshat M. S., Whang Y. E., Sawyers C. L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA. 95:1998;15587-15591.
34. Fritz G and Kaina B. RhoB encoding a UV-inducible ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase. J Biol Chem. 272:1997;30637-30644.
35. Fritz G., Kaina B., Aktories K. The Ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem. 270:1995;25172-15177.
36. Bernhard E. J., Kao G., Cox A. D. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res. 56:1996;1727-1730.
37. Bernhard E. J., McKenna W. G., Hamilton A. D. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations ofras oncogenes. Cancer Res. 58:1998;1754-1761.
38. Moasser M. M., Sepp-Lorenzino L., Kohl N. E. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA. 95:1998;1369-1374.